Host |
Mouse |
Klon |
6F3.1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Small intestine (Peyer’s patch), tonsil, thymus |
Verdünnung |
1:100 |
Isotyp |
IgG2a Kappa |
Verdünnung |
GST - tagged recombinant protein corresponding to human ROR gamma T |
Lokalisation |
Nucleus |
ROR gamma T
|
Biocare Medical |
6F3.1 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3208B |
-
|
Host |
Mouse |
Klon |
6F3.1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Small intestine (Peyer’s patch), tonsil, thymus |
Verdünnung |
- |
Isotyp |
IgG2a Kappa |
Verdünnung |
GST - tagged recombinant protein corresponding to human ROR gamma T |
Lokalisation |
Nucleus |
ROR gamma T
|
Biocare Medical |
6F3.1 |
6 ml |
Ready-to-use |
CE/IVD |
API3208AA |
-
|
Host |
Rabbit |
Klon |
EPMGHR2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung carcinoma |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
Lokalisation |
Cytoplasm (diffuse) |
ROS1
|
Biocare Medical |
EPMGHR2 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3240A |
-
|
Host |
Rabbit |
Klon |
EPMGHR2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung carcinoma |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
Lokalisation |
Cytoplasm (diffuse) |
ROS1
|
Biocare Medical |
EPMGHR2 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3240B |
-
|
Host |
Rabbit |
Klon |
EPMGHR2 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung carcinoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
Lokalisation |
Cytoplasm (diffuse) |
ROS1
|
Biocare Medical |
EPMGHR2 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3240G7 |
-
|
Host |
Rabbit |
Klon |
EPMGHR2 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung carcinoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
Lokalisation |
Cytoplasm (diffuse) |
ROS1
|
Biocare Medical |
EPMGHR2 |
6 ml |
Ready-to-use |
CE/IVD |
API3240AA |
-
|
Host |
Rabbit |
Klon |
EPMGHR2 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung carcinoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
Lokalisation |
Cytoplasm (diffuse) |
ROS1
|
Zytomed Systems GmbH |
EPMGHR2 |
6 ml |
Ready-to-use |
RUO |
RBG071 |
-
|
Host |
Rabbit |
Klon |
EPMGHR2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung carcinoma |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
Lokalisation |
Cytoplasm (diffuse) |
ROS1
|
Zytomed Systems GmbH |
EPMGHR2 |
0.1 ml |
Concentrate |
RUO |
RBK071-01 |
-
|
Host |
Rabbit |
Klon |
EPMGHR2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung carcinoma |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
Lokalisation |
Cytoplasm (diffuse) |
ROS1
|
Zytomed Systems GmbH |
EPMGHR2 |
0.5 ml |
Concentrate |
RUO |
RBK071-05 |
-
|
Host |
Rabbit |
Klon |
EPMGHR2 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung carcinoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human ROS1 aa 2050-2150. The exact sequence is proprietary. |
Lokalisation |
Cytoplasm (diffuse) |
ROS1
|
Diagnostic Biosystems |
EPMGHR2 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD108 |
-
|
Host |
Rabbit |
Klon |
ZR400 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Human brain, lung adenocarcinoma, or primary glioblastoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
Lokalisation |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
1 ml |
Concentrate |
RUO |
Z2756RL-R |
-
|
Host |
Rabbit |
Klon |
ZR400 |
Format |
reasy-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Human brain, lung adenocarcinoma, or primary glioblastoma |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
Lokalisation |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
7 ml |
reasy-to-use |
RUO |
Z2756RP-R |
-
|
Host |
Rabbit |
Klon |
ZR400 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Human brain, lung adenocarcinoma, or primary glioblastoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
Lokalisation |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
0.5 ml |
Concentrate |
RUO |
Z2756RS-R |
-
|
Host |
Rabbit |
Klon |
ZR400 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Human brain, lung adenocarcinoma, or primary glioblastoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
Lokalisation |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
0.1 ml |
Concentrate |
RUO |
Z2756RT-R |
-
|
Host |
Mouse |
Klon |
9H8 |
Format |
Concentrate |
Methode |
F, P, IP, IF, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
RPA (p34) (Replication Protein A)
|
Diagnostic Biosystems |
9H8 |
1 ml |
Concentrate |
CE/IVD |
MOB329 |
-
|
Host |
Mouse |
Klon |
9H8 |
Format |
Concentrate |
Methode |
F, P, IP, IF, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
RPA (p34) (Replication Protein A)
|
Diagnostic Biosystems |
9H8 |
0.1 ml |
Concentrate |
CE/IVD |
MOB329-01 |
-
|
Host |
Mouse |
Klon |
9H8 |
Format |
Concentrate |
Methode |
F, P, IP, IF, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
RPA (p34) (Replication Protein A)
|
Diagnostic Biosystems |
9H8 |
0.5 ml |
Concentrate |
CE/IVD |
MOB329-05 |
-
|
Host |
Mouse |
Klon |
4C4.9 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:150 - 1:300 |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified bovine brain S100 p |
Lokalisation |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
1ml |
Concentrate |
CE/IVD |
Z2055ML |
-
|
Host |
Mouse |
Klon |
4C4.9 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified bovine brain S100 p |
Lokalisation |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
7 ml |
Ready-to-use |
CE/IVD |
Z2055MP |
-
|
Host |
Mouse |
Klon |
4C4.9 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:150 - 1:300 |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified bovine brain S100 p |
Lokalisation |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
0.5 ml |
Concentrate |
CE/IVD |
Z2055MS |
-
|
Host |
Mouse |
Klon |
4C4.9 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:150 - 1:300 |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified bovine brain S100 p |
Lokalisation |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
0.1 ml |
Concentrate |
CE/IVD |
Z2055MT |
-
|
Host |
Rabbit |
Klon |
SP50 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the region of human S6 ribosomal that contains phosphorylated serines 235 and 236 |
Lokalisation |
Cytoplasm |
S6 Ribosomal (phospho S235/236)
|
Zytomed Systems GmbH |
SP50 |
1 ml |
Concentrate |
RUO |
519-3504 |
-
|
Host |
Mouse |
Klon |
SH-B1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin or Fast Enzyme |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
1 ml |
Concentrate |
CE/IVD |
MOB111 |
-
|
Host |
Mouse |
Klon |
SH-B1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin or Fast Enzyme |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB111-01 |
-
|
Host |
Mouse |
Klon |
SH-B1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin or Fast Enzyme |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB111-05 |
-
|
Host |
Mouse |
Klon |
4C4.9 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
4C4.9 |
1 ml |
Concentrate |
CE/IVD |
MOB377 |
-
|
Host |
Mouse |
Klon |
4C4.9 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
4C4.9 |
0.1 ml |
Concentrate |
CE/IVD |
MOB377-01 |
-
|
Host |
Mouse |
Klon |
4C4.9 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
4C4.9 |
0.5 ml |
Concentrate |
CE/IVD |
MOB377-05 |
-
|
Host |
Mouse |
Klon |
SH-B1 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Trypsin or Fast Enzyme |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM088 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Trypsin or Pepsin (optional) |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR008 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin or Pepsin (optional) |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP035 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin or Pepsin (optional) |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP035-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin or Pepsin (optional) |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP035-05 |
-
|
Host |
Rabbit |
Klon |
ZR115 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment corresponding to C-terminal of human S100P protein |
Lokalisation |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
1 ml |
Concentrate |
CE/IVD |
Z2419RL |
-
|
Host |
Rabbit |
Klon |
ZR115 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon cancer |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment corresponding to C-terminal of human S100P protein |
Lokalisation |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
7 ml |
Concentrate |
CE/IVD |
Z2419RP |
-
|
Host |
Rabbit |
Klon |
ZR115 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment corresponding to C-terminal of human S100P protein |
Lokalisation |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
0.5 ml |
Concentrate |
CE/IVD |
Z2419RS |
-
|
Host |
Rabbit |
Klon |
ZR115 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment corresponding to C-terminal of human S100P protein |
Lokalisation |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
0.1 ml |
Concentrate |
CE/IVD |
Z2419RT |
-
|
Host |
Sheep |
Klon |
Polyclonal |
Format |
Purified |
Methode |
Double Diffusion, Immunelectrophoresis |
Isotyp |
Mouse IgG1 |
Verdünnung |
Purified human amylase (Type XIII-A) from saliva |
Salivary Amylase
|
Zytomed Systems GmbH |
Polyclonal |
100 µl |
Purified |
RUO |
A12-6124 |
-
|
Host |
Mouse |
Klon |
6E3 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Seminoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
SALL4 (partial recombinant protein with GST tag) |
Lokalisation |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
1 ml |
Concentrate |
CE/IVD |
MOB591 |
-
|
Host |
Mouse |
Klon |
6E3 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Seminoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
SALL4 (partial recombinant protein with GST tag) |
Lokalisation |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB591-01 |
-
|
Host |
Mouse |
Klon |
6E3 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Seminoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
SALL4 (partial recombinant protein with GST tag) |
Lokalisation |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB591-05 |
-
|
Host |
Mouse |
Klon |
monoclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Seminoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Recombinant protein corresponding to the amino acid residues 954 to 10954 of human SALL4 protein |
Lokalisation |
Nucleus |
SALL4
|
Zytomed Systems GmbH |
monoclonal |
0.5 ml |
Concentrate |
RUO |
MSK079-05 |
-
|
Host |
Mouse |
Klon |
6E3 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Seminoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Verdünnung |
SALL4 (partial recombinant protein with GST tag) |
Lokalisation |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM591 |
-
|
Host |
Rabbit |
Klon |
SP281 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon, colon adenocarcinoms |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human SATB2 protein |
Lokalisation |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SP281 |
1 ml |
Concentrate |
RUO |
519-5814 |
-
|
Host |
Mouse |
Klon |
SATBA4B10 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Colorectal adenocarcinma |
Verdünnung |
- |
Isotyp |
IgG1 |
Verdünnung |
Recombinant protein fragment corresponding to the C-terminus of human SATB2 |
Lokalisation |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SATBA4B10 |
16 ml |
Ready-to-use |
RUO |
BMS068 |
-
|
Host |
Mouse |
Klon |
SATBA4B10 |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
EDTA |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Verdünnung |
Recombinant fragment of the C-terminal of human SATB2 |
Lokalisation |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SATBA4B10 |
0.5 ml |
Concentrate |
RUO |
MSK101-05 |
-
|
Host |
Rabbit |
Klon |
EP281 |
Format |
Concentrate |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to human SATB2 |
Lokalisation |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
1 ml |
Concentrate |
CE/IVD |
RMAB112 |
-
|
Host |
Rabbit |
Klon |
EP281 |
Format |
Concentrate |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to human SATB2 |
Lokalisation |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB112-01 |
-
|
Host |
Rabbit |
Klon |
EP281 |
Format |
Concentrate |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to human SATB2 |
Lokalisation |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB112-05 |
-
|
Host |
Rabbit |
Klon |
EP281 |
Format |
r-t-u |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
gebrauchsfertig |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to human SATB2 |
Lokalisation |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
6 ml |
r-t-u |
CE/IVD |
RMPD112 |
-
|